Holen Sie sich die Stockscreener-App
174.93
1.66%
-2.96
Handel nachbörslich:
174.60
-0.33
-0.19%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$177.89
Offen:
$177.67
24-Stunden-Volumen:
1.67M
Relative Volume:
0.86
Marktkapitalisierung:
$271.29B
Einnahmen:
$60.48B
Nettoeinkommen (Verlust:
$10.40B
KGV:
52.54
EPS:
3.3297
Netto-Cashflow:
$8.05B
1W Leistung:
-4.03%
1M Leistung:
-4.89%
6M Leistung:
+93.06%
1J Leistung:
+147.22%
1-Tages-Spanne:
$173.66
$177.80
1-Wochen-Bereich:
$173.66
$182.70
52-Wochen-Spanne:
$68.61
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
174.93 | 271.29B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,098.57 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
228.39 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
216.49 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
113.87 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
147.08 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
AstraZeneca (LSE:AZN) Stock Fair Value Edges Lower After Pipeline And Pricing Debate - Yahoo Finance
AstraZeneca (LSE:AZN) Stock Could Be 20.2% Undervalued After Recent Pullback - Yahoo Finance
Astrazeneca (AZN) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
AstraZeneca slides Thursday, underperforms market - MarketWatch
AstraZeneca rallies Wednesday, outperforms market - MarketWatch
The Zacks Analyst Blog Highlights Applied Materials, GE, AstraZeneca, Team and Applied Energetics - Zacks Investment Research
[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Top Stock Reports for Applied Materials, GE & AstraZeneca - Yahoo Finance
AstraZeneca (AZN) officer receives Ordinary Share award under incentive plan - Stock Titan
FDA Accepts AstraZeneca's Filing for Expanded Use of Ultomiris - Yahoo Finance Singapore
AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold? - TradingView
ASTRAZENECA : Gets a Buy rating from Jefferies - marketscreener.com
AstraZeneca says AI is raising its odds where most drugs fail - thestreet.com
EHA26: AstraZeneca battles Roche in untreated follicular lymphoma - Yahoo Finance
This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod - Benzinga
AstraZeneca slips Monday, underperforms market - MarketWatch
AstraZeneca's Truqap Wins FDA Nod for Prostate Cancer Indication - Yahoo Finance
FDA approves AstraZeneca’s Truqap for PTEN-deficient prostate cancer in US - Investing.com
US approves AstraZeneca (NYSE: AZN) Truqap combo for PTEN-deficient metastatic prostate cancer - Stock Titan
DEFINED WEALTH MANAGEMENT, LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca PLC (AZN) Stock Analysis: Exploring a 25.59% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
FDA Grants Priority Review to AstraZeneca’s Ultomiris for Rare Kidney Disease Treatment (AZN) - Yahoo Finance UK
Astrazeneca secures US approval for Truqap combo in PTEN‑deficient prostate cancer - Sharecast.com
AstraZeneca's Ultomiris wins US FDA priority review in kidney disease - marketscreener.com
Astrazeneca Plc Gains US Approval For Truqap In PTEN-deficient Prostate Cancer - DirectorsTalk Interviews
TRUQAP Approval Adds Precision Prostate Cancer Upside To AstraZeneca Valuation - Yahoo Finance
AstraZeneca Receives Priority Review in the US for ULTOMIRIS as Treatment for Adults With Immunoglobulin A Nephropathy - marketscreener.com
AZN Stock Quote Price and Forecast - CNN
AstraZeneca | Pharmaceuticals, Vaccines, & Facts | Britannica Money - Britannica
CVT Nasdaq-100 Index Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
AVIP Nasdaq-100 Index Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca says Truqap combination approved in US for prostate cancer - London South East
AstraZeneca (AZN) Gains from New Diagnostic Test Approval - GuruFocus
AstraZeneca (AZN) Secures U.S. Approval for Innovative Prostate Cancer Treatment - GuruFocus
AstraZeneca Truqap Ok'd in U.S. for prostate cancer (AZN:NYSE) - Seeking Alpha
AstraZeneca : Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer - marketscreener.com
AstraZeneca PLC Stock (US6549022043): ADR inches higher on Nasdaq as pharma heavyweight stays in foc - AD HOC NEWS
AstraZeneca PLC Stock (US6549022043): Deutsche Bank sticks to Sell rating as shares edge higher - AD HOC NEWS
AstraZeneca PLC (AZN) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow - Seeking Alpha
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Jazz, AstraZeneca, Astellas: Foreign healthcare's strongest quant picks - MSN
AstraZeneca PLC Stock (US6549022043): Obesity Drug Elecoglipron Heads Into Phase 3 As Shares Climb - AD HOC NEWS
ASTRAZENECA : Deutsche Bank maintains a Sell rating - marketscreener.com
ADA 2026: AstraZeneca To Move Fast On Obesity And Heart Pill Combinations - Citeline News & Insights
Jim Cramer on AstraZeneca: “On Track to Hit the Ambitious Long-Term Financial Targets” - Yahoo Finance
Hansa Biopharma appoints Head of Business Development from AstraZeneca - marketscreener.com
AstraZeneca advances oral GLP-1 elecoglipron into phase 3 - MSN
AstraZeneca PLC stock (US6549022043): obesity drug data and pipeline momentum keep investors alert - AD HOC NEWS
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials - Benzinga
Functional genomics and AI drive novel target discovery at AstraZeneca - Select Science
State Street Premier Growth Equity V.I.S. Fund's AstraZeneca PLC(AZN) Holding History - GuruFocus
Finanzdaten der Astrazeneca Plc-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):